论文信息 - Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU - 字舞流文

Peginterferon beta-1a in relapsing–remitting multiple sclerosis: a guide to its use in the EU

Sheridan M. Hoy | K. Lyseng-Williamson

[1] D. Arnold,et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE , 2015, Multiple sclerosis.

[2] Sheridan M. Hoy. Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis , 2015, CNS Drugs.

[3] D. Arnold,et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study , 2014, The Lancet Neurology.

[4] Nathalie Girouard,et al. Patient considerations in the management of multiple sclerosis: development and clinical utility of oral agents , 2011, Patient preference and adherence.

[5] I. Nestorov,et al. PEGylated interferon beta-1a: meeting an unmet medical need in the treatment of relapsing multiple sclerosis. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[6] J. Stadler,et al. PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies , 2007, Drug Metabolism and Disposition.